Cargando…

PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway

Many long noncoding RNAs have been implicated in tumorigenesis and chemoresistance; however, the underlying mechanisms are not well understood. We investigated the role of PRKAR1B-AS2 long noncoding RNA in ovarian cancer (OC) and chemoresistance and identified potential downstream molecular circuitr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elsayed, Abdelrahman M., Bayraktar, Emine, Amero, Paola, Salama, Salama A., Abdelaziz, Abdelaziz H., Ismail, Raed S., Zhang, Xinna, Ivan, Cristina, Sood, Anil K., Lopez-Berestein, Gabriel, Rodriguez-Aguayo, Cristian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918312/ https://www.ncbi.nlm.nih.gov/pubmed/33668685 http://dx.doi.org/10.3390/ijms22041882

Ejemplares similares

Back to the Future: Rethinking the Great Potential of lncRNA(S) for Optimizing Chemotherapeutic Response in Ovarian Cancer
por: Elsayed, Abdelrahman M., et al.
Publicado: (2020)

Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer
por: Attia, Yasmin M., et al.
Publicado: (2020)

Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update
por: Bayraktar, Emine, et al.
Publicado: (2023)

An Overview of the Immune Modulatory Properties of Long Non-Coding RNAs and Their Potential Use as Therapeutic Targets in Cancer
por: Martinez-Castillo, Moises, et al.
Publicado: (2023)

Inactivating Mutations of the IK Gene Weaken Ku80/Ku70-Mediated DNA Repair and Sensitize Endometrial Cancer to Chemotherapy
por: Gao, Chao, et al.
Publicado: (2021)

Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer
por: Lara, Olivia D., et al.
Publicado: (2020)

Determination and validation of mTOR kinase-domain 3D structure by homology modeling
por: Lakhlili, Wiame, et al.
Publicado: (2015)

PRKAR1A and Thyroid Tumors
por: Pitsava, Georgia, et al.
Publicado: (2021)

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
por: Yuan, RuiRong, et al.
Publicado: (2009)

PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis
por: Rodriguez-Aguayo, Cristian, et al.
Publicado: (2019)

Structure–activity relationships study of mTOR kinase inhibition using QSAR and structure-based drug design approaches
por: Lakhlili, Wiame, et al.
Publicado: (2016)

Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma
por: Caro-Vegas, Carolina, et al.
Publicado: (2019)

Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy
por: Mangala, Lingegowda S., et al.
Publicado: (2021)

Aptamers: Novel Therapeutics and Potential Role in Neuro-Oncology
por: Amero, Paola, et al.
Publicado: (2020)

Non-Coding RNAs: Foes or Friends for Targeting Tumor Microenvironment
por: Szymanowska, Anna, et al.
Publicado: (2023)

Corrigendum to “PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis” [EBioMedicine 40 (2019) 290-304]
por: Rodriguez-Aguayo, Cristian, et al.
Publicado: (2022)

MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors
por: Clegg, Nicola J., et al.
Publicado: (2011)

Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer
por: Dasari, Santosh K., et al.
Publicado: (2023)

Aurora-A Induces Chemoresistance Through Activation of the AKT/mTOR Pathway in Endometrial Cancer
por: Wu, Jun, et al.
Publicado: (2019)

Novel Mutation in PRKAR1A in Carney Complex
por: Park, Ko Un, et al.
Publicado: (2012)

Hematopoietic neoplasms in Prkar2a-deficient mice
por: Saloustros, Emmanouil, et al.
Publicado: (2015)

LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway
por: Li, Xiaoyan, et al.
Publicado: (2014)

Osteopontin is Critical for Hyperactive mTOR-Induced Tumorigenesis in Oral Squamous Cell Carcinoma
por: Gan, Ning, et al.
Publicado: (2017)

MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase
por: Bayraktar, Recep, et al.
Publicado: (2016)

LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer
por: Feng, Mengyu, et al.
Publicado: (2018)

Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer
por: Kanlikilicer, Pinar, et al.
Publicado: (2018)

Corrigendum to ‘Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer’ [EBioMedicine 38 (2018) 100–112]
por: Kanlikilicer, Pinar, et al.
Publicado: (2020)

Correction: MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase
por: Bayraktar, Recep, et al.
Publicado: (2023)

The Paradox of Akt-mTOR Interactions
por: Vadlakonda, Lakshmipathi, et al.
Publicado: (2013)

Roles of Src family kinase, Ras, and mTOR signaling in intestinal epithelial homeostasis and tumorigenesis
por: Matozaki, Takashi, et al.
Publicado: (2020)

RagC GTPase regulates mTOR to promote chemoresistance in senescence-like HepG2 cells
por: Jiang, Wei, et al.
Publicado: (2022)

Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models
por: Kanlikilicer, Pinar, et al.
Publicado: (2017)

Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges
por: Szymanowski, Wojciech, et al.
Publicado: (2023)

Long noncoding RNA PICSAR/miR‐588/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K/AKT/mTOR signaling pathway
por: Liu, Zhikui, et al.
Publicado: (2020)

Overexpression of long noncoding RNA GAS5 suppresses tumorigenesis and development of gastric cancer by sponging miR-106a-5p through the Akt/mTOR pathway
por: Dong, Shuaijun, et al.
Publicado: (2019)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Lysosomal TMEM9‐LAMTOR4‐controlled mTOR signaling integrity is required for mammary tumorigenesis
por: Zhang, Shengzhe, et al.
Publicado: (2022)

Dichloroacetate Overcomes Oxaliplatin Chemoresistance in Colorectal Cancer through the miR-543/PTEN/Akt/mTOR Pathway
por: Liang, Yu, et al.
Publicado: (2019)

Recurrent somatic mutations of PRKAR1A in isolated cardiac myxoma
por: He, Jian, et al.
Publicado: (2017)

PRKAR1A deficiency impedes hypertrophy and reduces heart size
por: Liu, Yuening, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ejagrm7kd6lc49n6e18jf0vrb4